8.25 USD
-0.15
1.79%
At close Dec 20, 4:00 PM EST
After hours
8.25
+0.00
0.00%
1 day
-1.79%
5 days
1.23%
1 month
4.96%
3 months
1.60%
6 months
-10.13%
Year to date
-24.24%
1 year
-21.13%
5 years
18.88%
10 years
89.66%
 

About: Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Employees: 1,101

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

6% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 33

4.33% less ownership

Funds ownership: 31.13% [Q2] → 26.8% (-4.33%) [Q3]

9% less funds holding

Funds holding: 110 [Q2] → 100 (-10) [Q3]

25% less capital invested

Capital invested by funds: $92.2M [Q2] → $69.4M (-$22.7M) [Q3]

43% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 23

71% less call options, than puts

Call options by funds: $6K | Put options by funds: $21K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
33%
upside
Avg. target
$14
70%
upside
High target
$17
106%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
39% 1-year accuracy
60 / 154 met price target
106%upside
$17
Buy
Reiterated
6 Dec 2024
RBC Capital
Shagun Singh
51% 1-year accuracy
40 / 78 met price target
33%upside
$11
Outperform
Maintained
8 Oct 2024

Financial journalist opinion

Based on 10 articles about ZYXI published over the past 30 days

Positive
Proactive Investors
4 days ago
Zynex partners with VA to offer pain management solutions for veterans
Zynex Inc (NASDAQ:ZYXI) has announced a new partnership with Veterans Affairs Medical Centers (VAMCs) across the United States, a significant opportunity to expand the reach of its noninvasive medical devices for pain management and rehabilitation. This collaboration provides an opportunity to expand sales of Zynex's pain management solutions within the largest healthcare network in the US, which serves over 9 million enrolled veterans annually and accounts for more than $112 billion in annual healthcare spending.
Zynex partners with VA to offer pain management solutions for veterans
Neutral
PRNewsWire
4 days ago
Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States
VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually ENGLEWOOD, Colo. , Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States.
Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States
Positive
Proactive Investors
1 week ago
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI
Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to employee dedication and innovative pain management products like braces and cold therapy devices.
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI
Positive
Proactive Investors
1 week ago
Zynex study highlights precision of laser-based pulse oximeter in reducing racial bias
Zynex Inc (NASDAQ:ZYXI) announced findings from study demonstrating that its NiCO laser pulse oximeter eliminates the impact of skin pigmentation on blood oxygenation (SpO2) measurements. The University of California, San Francisco-led study compared Zynex's NiCO device to conventional LED-based pulse oximeters.
Zynex study highlights precision of laser-based pulse oximeter in reducing racial bias
Neutral
PRNewsWire
1 week ago
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters
ENGLEWOOD, Colo. , Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of California, San Francisco (UCSF) Hypoxia Lab.
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters
Positive
Zacks Investment Research
1 week ago
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial
Neutral
PRNewsWire
2 weeks ago
Zynex Announces Completion of Its Laser Pulse Oximetry Trial
ENGLEWOOD, Colo. , Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has completed its clinical verification trial for their NiCO™ pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University.
Zynex Announces Completion of Its Laser Pulse Oximetry Trial
Positive
Proactive Investors
2 weeks ago
Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeter
Zynex Inc (NASDAQ:ZYXI) has announced its membership in the Collaborative Community of the Open Oximetry Project as an industry member. This initiative, led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, aims to enhance the safety and accuracy of pulse oximeters across diverse populations.
Zynex joins Open Oximetry Project as it advances innovative NiCO pulse oximeter
Neutral
PRNewsWire
2 weeks ago
Zynex Announces Open Oximetry Project Membership
ENGLEWOOD, Colo. , Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.
Zynex Announces Open Oximetry Project Membership
Positive
Proactive Investors
3 weeks ago
Zynex leverages multi-modality NexWave device to transform pain management
Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, reimbursable solutions. While the company has successfully capitalized on the growing demand for non-opioid therapies, staying ahead will depend on its ability to innovate and adapt to a rapidly evolving medical device landscape.
Zynex leverages multi-modality NexWave device to transform pain management
Charts implemented using Lightweight Charts™